Table 3.
Characteristic | Reported Side-Effects | OR (95% CI) | p | |
---|---|---|---|---|
Yes (n = 250) | No (n = 187) | |||
Age group (years) | ||||
20–30 (n = 169) | 94 (55.6) | 75 (44.4) | 1 | |
31–40 (n = 202) | 115 (56.9) | 87 (43.1) | 1.06 (0.70, 1.60) | 0.801 |
41–50 (n = 50) | 29 (58.0) | 21 (42.0) | 1.10 (0.58, 2.09) | 0.766 |
>50 (n = 16) | 12 (75.0) | 4 (25.0) | 2.39 (0.74, 7.72) | 0.134 |
Gender | ||||
Female (n = 283) | 160 (56.5) | 123 (43.5) | 0.93 (0.62, 1.38) | 0.701 |
Male (n = 154) | 90 (58.4) | 64 (41.6) | 1 | |
Nationality | ||||
Saudi (n = 190) | 138 (73.8) | 49 (26.2) | 3.47 (2.30, 5.23) | <0.001 * |
Non-Saudi (n = 254) | 112 (44.8) | 138 (55.2) | 1 | |
Marital status | ||||
Married (n = 255) | 145 (57.2) | 105 (42.0) | 1.08 (0.74, 1.58) | 0.699 |
Single (n = 189) | 105 (56.1) | 82 (43.9) | 1 | |
Residence | ||||
Jazan (n = 378) | 205 (54.2) | 173 (45.8) | 0.36 (0.15, 0.86) | 0.017 |
Sabia (n = 29) | 22 (75.9) | 7 (24.1) | 0.96 (0.29, 3.18) | 0.924 |
Abu Arish (n = 30) | 23 (76.7) | 7 (23.3) | 1 | |
Occupation | ||||
Medical (n = 245) | 125 (51.0) | 120 (49.0) | 0.56 (0.38, 0.82) | 0.003 * |
Nonmedical (n = 192) | 125 (65.1) | 67 (34.9) | 1 | |
Diagnosed previously with COVID-19 | ||||
Yes (n = 55) | 28 (50.9) | 27 (49.1) | 0.75 (0.43, 1.32) | 0.313 |
No (n = 382) | 222 (58.1) | 160 (41.9) | 1 |
OR, odds ratio; CI, confidence interval. Significant association (unadjusted p < 0.05). * Significant association (using the Bonferroni–Holm correction for multiple comparisons).